Shares of BioAge Labs (BIOA) continued to spike for the second consecutive session on Tuesday in reaction to updated results ...
The combination of an experimental BioAge Labs drug with the approved Eli Lilly obesity medication Zepbound has hit a major setback: a safety signal observed in some clinical trial participants that ...
Funding to advance Phase 2 clinical trials of azelaprag, an apelin receptor (APJ) agonist, in combination with Lilly’s Zepbound (tirzepatide) and therapeutic pipeline Azelaprag improves metabolic and ...
First BGE-102 MAD cohort completed in obese individuals with elevated hsCRP receiving 120 mg QD; demonstrated rapid and profound reduction in ...
BioAge Labs will analyze 17,000 samples from Norway's HUNT Biobank to enhance drug target discovery for aging-related diseases. BioAge Labs, Inc. has announced a new initiative to analyze over 17,000 ...
Shares of BioAge (NASDAQ:BIOA) cratered 70% Friday in post-market trading after the company said it was discontinuing a Phase 2 study for its weight-loss drug azelaprag over safety concerns. Of the ...
CHENGDU, China, Sept. 15, 2025 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH), congratulates its partner BioAge Labs ...
EMERYVILLE, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (BIOA) ("BioAge", “the Company”), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic ...
SAN DIEGO--(BUSINESS WIRE)--The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of BioAge Labs, Inc. (NASDAQ: BIOA) stock pursuant and/or traceable to BioAge Labs’ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results